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Another option for patients  
with liver disease 
Currently used to treat hepatic encephalopathy, 
rifaximin is effective at preventing this common 
complication of chronic liver disease, as well.
Practice changer
Consider prescribing rifaximin for patients 
with hepatic encephalopathy, not only as a 
treatment for acute episodes but also to pre-
vent a recurrence.1
strength of recommendation: 
A: Based on a high-quality randomized con-
trolled trial (RCT) 
Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic 
encephalopathy. N Engl J Med. 2010;362:1071-1081.1 
illustrative case 
a 64-year-old patient with chronic liver dis-
ease has been hospitalized on 3 occasions for 
hepatic encephalopathy, all while he was tak-
ing lactulose. he is still taking it, but wonders 
if there are other ways to prevent future epi-
sodes of hepatic encephalopathy. What can 
you tell him? 
Characterized by periods of impaired cognition of varying severity, hepatic encephalopathy is a common com-
plication of chronic liver disease—and a fre-
quent cause of hospitalization, morbidity, and 
mortality in this patient population. Up to 70% 
of patients with cirrhosis may have some de-
gree of hepatic encephalopathy,2 which can 
occur without provocation or be triggered by 
gastrointestinal (GI) bleeding, infection, kid-
ney disease, electrolyte abnormalities, shunt 
placement, respiratory disease, or anemia. 
Hepatic encephalopathy is thought to be 
caused by elevated ammonia levels. 
Current first-line treatment 
is not problem-free 
Patients with chronic liver disease and hepatic 
encephalopathy are often placed on nonab-
sorbable disaccharides, such as lactulose, 
to prevent recurrent hepatic encephalopa-
thy. However, disaccharides’ effectiveness as 
prophylaxis is unproven.3 In addition, many 
patients have difficulty tolerating lactulose 
because of its taste and GI side effects.
A 2004 Cochrane review examined the ef-
fectiveness of lactulose in preventing hepatic en-
cephalopathy.3 The reviewers also compared the 
effectiveness of an oral antibiotic, rifaximin, with 
lactulose for this purpose. Rifaximin, like lactu-
lose, is believed to work by reducing ammonia in 
the gut. The antibiotic is a well-established treat-
ment for acute hepatic encephalopathy, but not 
widely used for preventive purposes. 
The reviewers found rifaximin to be more 
effective compared with lactulose at prevent-
ing recurrent episodes of hepatic encephalopa-
thy (number needed to treat [NNT]=11).3 Other 
studies have also suggested that the antibiotic, 
which has minimal systemic absorption, may 
be as effective as, or more effective than, lactu-
lose in preventing recurrences.4,5 The new RCT 
detailed in this PURL took another look at rifaxi-
min’s usefulness as prophylaxis. 
study summary
Patients on rifaximin  
had better outcomes
The study by Bass et al was a double-blinded 
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RCT enrolling 299 patients with chronic liver 
disease.1 Criteria for inclusion were age 
≥18 years, a minimum of 2 prior episodes of 
hepatic encephalopathy, remission from he-
patic encephalopathy at the time of enroll-
ment, and mild to moderate liver disease 
severity, defined as a score ≤25 on the Model 
for End-Stage Liver Disease (MELD) scale.6 
(The scale ranges from 6 to 40, with higher 
numbers indicating more severe disease.) The 
researchers excluded patients for whom liver 
transplant was imminent and those with con-
ditions that precipitate hepatic encephalopa-
thy, as described earlier. 
Patients were assigned to either rifaximin 
550 mg twice a day (140 patients) or placebo 
(159 patients) for 6 months. Both groups had 
similar baseline characteristics, including 
a high percentage of subjects (>90%) with 
concomitant lactulose use. The research-
ers assessed the patients at clinic visits every 
2 weeks, both by their Conn score (the scale 
commonly used to grade hepatic encephalop-
athy) and grade of asterixis, and during tele-
phone calls on alternate weeks. Analysis was 
by intention-to-treat. 
The primary endpoint was the mean 
time to the first episode of hepatic encepha-
lopathy, which was 130.0 (+56.5) days in the 
rifaximin group and 105.7 (+62.7) days in the 
control group. During the 6-month study pe-
riod, 22% of patients in the rifaximin group 
experienced a breakthrough hepatic encepha-
lopathy event, vs 45.9% of the placebo group 
(95% confidence interval, 0.28-0.64; P<0.001; 
hazard ratio=0.42; NNT=9). Both groups had 
high rates of compliance (~84%) and high 
rates of adverse events (80%). Two patients 
receiving rifaximin experienced Clostridium 
difficile infections, from which they recovered. 
Death rates were similar in both groups, and 
were attributed to liver disease progression. 
What’s neW?
FDA approves rifaximin  
to prevent recurrence
This trial adds further support for the use 
of rifaximin in the prevention of recurrent 
episodes of hepatic encephalopathy. In addi-
tion, the US Food and Drug Administration 
approved the antibiotic for that purpose in 
March of this year.7 Given the lack of proven, 
well-tolerated treatments to prevent hepatic 
encephalopathy in patients with liver disease 
and the significant morbidity and mortality 
associated with this complication, family phy-
sicians should consider prescribing rifaximin 
for patients with prior episodes of hepatic 
encephalopathy. Rifaximin resistance is not 
common and, because its activity is concen-
trated in the gut, resistance is unlikely to be-
come a significant issue. 
caveats
long-term safety has not  
been established
Because of this study’s short duration 
(6 months) and relatively small sample size, 
we cannot be certain of its long-term effects or 
safety. However, patients with advanced liver 
disease and recurrent hepatic encephalopathy 
have a poor prognosis, and a treatment that is ef-
fective, even if just for 6 months, is meaningful.
Also, because this study excluded pa-
tients with more severe liver disease (MELD 
score >25), we have no data to guide the use of 
rifaximin in this patient population. However, 
the mechanism of action and risk of adverse 
effects are likely to be similar. 
Finally, the manufacturer of the drug was 
involved in the study design, data collection, 
data analysis, and manuscript preparation. 
challenges to imPlementation
Drug cost and coverage  
are potential barriers 
Rifaximin is available in the United States in 
200- and 550-mg tablets, so it can be dosed at 
1100 or 1200 mg per day in divided doses. The 
drug is not generic, however, and is costly: A 
month’s supply of the 550-mg tablets is about 
$1300 (a supply of the 200-mg tablets is even 
more expensive),8 and the drug may not be 
covered by insurance.                                           JFP
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